Peijia Medical Ltd. (9996) AI Stock Analysis

• Market Cap: €4.63B
• Dividend Yield: N/A
• Average Volume (3M): 2.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 28.66%
• EPS Growth: 9.02%
• Country: HK
• Employees: 1,047
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.11
• Shares Outstanding: 669,512,900
• 10 Day Avg. Volume: 1,828,724
• 30 Day Avg. Volume: 2,409,437
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €6.98
• Price Target Upside: 3.76% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: HK$7.00 ▲(4.01% Upside)

Peijia Medical Ltd.'s overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis indicates weak momentum, and valuation metrics highlight ongoing unprofitability. The absence of earnings call insights and corporate events further limits the score.

Peijia Medical Ltd. Business Overview & Revenue Model

Company Description

Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.

How the Company Makes Money

Peijia Medical Ltd. generates revenue through the sale of its medical devices, which are primarily used in minimally invasive procedures. The company's key revenue streams include sales of its structural heart disease products, such as transcatheter valve systems, and its neurointerventional devices, which are designed for the treatment of cerebrovascular diseases. Peijia Medical's earnings are supported by its extensive research and development efforts and strategic partnerships with healthcare providers and distributors that facilitate market penetration and product adoption in China and potentially other international markets.

Peijia Medical Ltd. Financial Statement Overview

Summary

Peijia Medical Ltd. demonstrates strong revenue growth but struggles with profitability and cash flow. The robust equity position provides some stability, yet a clear path to sustainable profitability is essential.

Income Statement

Peijia Medical Ltd. shows significant revenue growth from 2023 to 2024, with a 39.5% increase. However, the company continues to experience negative EBIT and net income, resulting in negative profit margins. This indicates ongoing challenges in attaining profitability despite growing sales.

Balance Sheet

The company maintains a strong equity position, with a high equity ratio of 75.4% in 2024, reflecting financial stability. However, the debt-to-equity ratio has increased slightly, and the company is still not profitable, which could pose risks if financial conditions change.

Cash Flow

Peijia Medical Ltd. continues to face challenges in cash flow, with zero free cash flow in 2024. The absence of operating cash flow growth and reliance on external financing over the years highlight liquidity risks despite a reduction in net debt.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	615.48M	441.13M	250.83M	136.53M	38.66M
Gross Profit	433.62M	325.37M	176.20M	95.65M	25.22M
EBITDA	-192.93M	-348.52M	-359.90M	-546.54M	-190.87M
Net Income	-226.58M	-392.52M	-407.81M	-574.22M	-2.07B
Balance Sheet
Total Assets	2.69B	2.67B	3.32B	3.16B	2.88B
Cash, Cash Equivalents and Short-Term Investments	712.52M	942.92M	1.74B	2.30B	2.46B
Total Debt	253.40M	221.13M	131.88M	7.63M	9.13M
Total Liabilities	644.11M	397.88M	678.86M	144.48M	67.99M
Stockholders Equity	2.03B	2.27B	2.64B	3.02B	2.81B
Cash Flow
Free Cash Flow	-285.29M	-899.67M	-506.61M	-506.11M	-206.35M
Operating Cash Flow	-5.18M	-583.49M	-376.20M	-436.37M	-181.10M
Investing Cash Flow	-140.38M	-386.29M	-463.28M	-424.75M	-12.48M
Financing Cash Flow	10.38M	85.11M	117.44M	741.98M	2.34B

Peijia Medical Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9996, the sentiment is Negative. The current price of 6.73 is below the 20-day moving average (MA) of 7.54, below the 50-day MA of 8.07, and above the 200-day MA of 5.64, indicating a neutral trend. The MACD of -0.31 indicates Positive momentum. The RSI at 32.34 is Neutral, neither overbought nor oversold. The STOCH value of 12.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9996.

Peijia Medical Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2172	66 Neutral	8.30B	37.49	14.86%	1.15%	-5.18%	-9.69%
1858	66 Neutral	8.85B	45.35	4.43%	0.91%	-32.05%	-54.47%
2190	59 Neutral	8.29B	48.92	3.23%	0.43%	35.01%	483.73%
2160	51 Neutral	3.55B	645.45	-2.26%	―	-4.38%	0.00%
0853	46 Neutral	26.96B	-20.07	-35.47%	―	-1.04%	60.66%
9996	41 Neutral	€4.63B	―	-11.20%	―	28.66%	9.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Peijia Medical Ltd. Corporate Events

Peijia Medical Ltd. Reports Strong Revenue Growth and Operational Improvements in H1 2025

Peijia Medical Ltd. reported a 17.3% increase in revenue for the first half of 2025, driven by robust sales growth in its TAVR and neurointerventional businesses. The company achieved significant market share gains in China’s transfemoral TAVR market and launched new premium products, contributing to a 24.0% rise in TAVR-related sales. Neurointerventional product sales also grew by 12.2%, supported by market penetration of existing products and the introduction of the YonFlow Flow Diverting Stent. Operational efficiency improvements led to a 42.4% increase in the Neurointerventional Business segment profit and a narrowing of losses in the Transcatheter Valve Therapeutic Business. Overall, Peijia Medical’s strategic initiatives and market education efforts have strengthened its position as a leading TAVR brand in China.

The most recent analyst rating on (HK:9996) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Ltd. Schedules Board Meeting for Interim Results Review

Peijia Medical Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for the payment of an interim dividend, highlighting the company’s ongoing financial activities and potential shareholder returns.

The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Reports Strong Growth in H1 2025

Peijia Medical Ltd. announced unaudited operating statistics for the first half of 2025, highlighting a revenue increase driven by market share gains in the TAVR sector and the introduction of premium products. The company expanded its TAVR portfolio into over 70 new hospitals, achieving significant growth in implantations. The launch of new neurointerventional products also contributed to robust performance, indicating strong market positioning and potential future growth.

The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Achieves Milestone with First Implant in Global Study of MonarQ TTVR® System

Peijia Medical Ltd. has announced the successful completion of the first patient implant in the Global Clinical Study of its MonarQ TTVR® system, an innovative device designed to treat Tricuspid Regurgitation. This marks a significant milestone for the company, as it officially launches the global study and advances its pipeline development in this area, potentially impacting its market position and offering new treatment options for patients.

The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Enhances Governance with Nomination Committee

Peijia Medical Limited has outlined the terms of reference for its Nomination Committee, which was established to identify and recommend suitable candidates for the company’s board of directors. The committee, composed mainly of independent non-executive directors, is responsible for developing nomination guidelines and ensuring compliance with relevant laws and regulations. This move is expected to enhance the governance framework of Peijia Medical, potentially strengthening its industry position and stakeholder confidence.

The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

Peijia Medical Ltd. Announces Board Composition and Roles

Peijia Medical Ltd. has announced the composition of its board of directors and their roles within the company. The board comprises executive, non-executive, and independent non-executive directors, with specific members assigned to the audit, remuneration, and nomination committees. This announcement provides clarity on the governance structure of the company, which could impact its strategic decisions and stakeholder confidence.

The most recent analyst rating on (HK:9996) stock is a Buy with a HK$6.25 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.